<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension - Wang, GM - 2020 | Cochrane Library</title> <meta content="Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension - Wang, GM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012569.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension - Wang, GM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012569.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012569.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension" name="citation_title"/> <meta content="Gan Mi Wang" name="citation_author"/> <meta content="School of Pharmacy, Fudan University" name="citation_author_institution"/> <meta content="Liang Jin Li" name="citation_author"/> <meta content="School of Pharmacy, Fudan University" name="citation_author_institution"/> <meta content="Wen Lu Tang" name="citation_author"/> <meta content="School of Pharmacy, Fudan University" name="citation_author_institution"/> <meta content="tangwenlu@fudan.edu.cn" name="citation_author_email"/> <meta content="James M Wright" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012569.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/10/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012569.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012569.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012569.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amides [adverse effects, therapeutic use]; Angiotensin-Converting Enzyme Inhibitors [adverse effects, *therapeutic use]; Antihypertensive Agents [adverse effects, *therapeutic use]; Cardiovascular Diseases [epidemiology]; Cause of Death; Fumarates [adverse effects, therapeutic use]; Heart Rate [drug effects]; Irbesartan [therapeutic use]; Kidney Failure, Chronic [epidemiology]; Lisinopril [therapeutic use]; Myocardial Infarction [epidemiology]; Patient Dropouts [statistics &amp; numerical data]; Ramipril [therapeutic use]; Randomized Controlled Trials as Topic; Renin [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012569.pub2&amp;doi=10.1002/14651858.CD012569.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012569\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012569\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ru","pt","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012569.pub2",title:"Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension",firstPublishedDate:"Oct 22, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012569.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012569.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012569.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012569.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012569.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012569.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012569.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012569.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012569.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012569.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5847 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012569.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-sec-0063"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-sec-0057"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/appendices#CD012569-sec-0068"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/supinfo/CD012569StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/supinfo/CD012569StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information#CD012569-cr-0004">Gan Mi Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information#CD012569-cr-0005">Liang Jin Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information#CD012569-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Wen Lu Tang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information#CD012569-cr-0007">James M Wright</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information/en#CD012569-sec-0072">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 October 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012569.pub2">https://doi.org/10.1002/14651858.CD012569.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012569-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012569-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012569-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012569-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012569-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD012569-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012569-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012569-abs-0001" lang="en"> <section id="CD012569-sec-0001"> <h3 class="title" id="CD012569-sec-0001">Background</h3> <p>Renin inhibitors (RIs) reduce blood pressure more than placebo, with the magnitude of this effect thought to be similar to that for angiotensin converting enzyme (ACE) inhibitors. However, a drug's efficacy in lowering blood pressure cannot be considered as a definitive indicator of its effectiveness in reducing mortality and morbidity. The effectiveness and safety of RIs compared to ACE inhibitors in treating hypertension is unknown. </p> </section> <section id="CD012569-sec-0002"> <h3 class="title" id="CD012569-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of renin inhibitors compared to ACE inhibitors in people with primary hypertension. </p> </section> <section id="CD012569-sec-0003"> <h3 class="title" id="CD012569-sec-0003">Search methods</h3> <p>The Cochrane Hypertension Group Information Specialist searched the following databases for randomized controlled trials up to August 2020: the Cochrane Hypertension Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted authors of relevant papers about further published and unpublished work. The searches had no language restrictions. </p> </section> <section id="CD012569-sec-0004"> <h3 class="title" id="CD012569-sec-0004">Selection criteria</h3> <p>We included randomized, active‐controlled, double‐blinded studies (RCTs) with at least four weeks follow‐up in people with primary hypertension, which compared renin inhibitors with ACE inhibitors and reported morbidity, mortality, adverse events or blood pressure outcomes. We excluded people with proven secondary hypertension. </p> </section> <section id="CD012569-sec-0005"> <h3 class="title" id="CD012569-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected the included trials, evaluated the risks of bias and entered the data for analysis. </p> </section> <section id="CD012569-sec-0006"> <h3 class="title" id="CD012569-sec-0006">Main results</h3> <p>We include 11 RCTs involving 13,627 participants, with a mean baseline age from 51.5 to 74.2 years. Follow‐up duration ranged from four weeks to 36.6 months. </p> <p>There was no difference between RIs and ACE inhibitors for the outcomes: all‐cause mortality: risk ratio (RR) 1.05, 95% confidence interval (CI) 0.93 to 1.18; 5 RCTs, 5962 participants; low‐certainty evidence; total myocardial infarction: RR 0.86, 95% CI 0.22 to 3.39; 2 RCTs, 957 participants; very low‐certainty evidence; adverse events: RR 0.98, 95% CI 0.93 to 1.03; 10 RTCs, 6007 participants;  moderate‐certainty evidence; serious adverse events: RR 1.21, 95% CI 0.89 to 1.64; 10 RTCs, 6007 participants; low‐certainty evidence; and withdrawal due to adverse effects: RR 0.85, 95% CI 0.68 to 1.06; 10 RTCs, 6008 participants; low‐certainty evidence. No data were available for total cardiovascular events, heart failure, stroke, end‐stage renal disease or change in heart rate. Low‐certainty evidence suggested that RIs reduced systolic blood pressure: mean difference (MD) −1.72, 95% CI −2.47 to −0.97; 9 RCTs, 5001 participants;  and diastolic blood pressure: MD −1.18, 95% CI −1.65 to −0.72; 9 RCTs, 5001 participants,  to a greater extent than ACE inhibitors, but we judged this to be more likely due to bias than a true effect.  </p> </section> <section id="CD012569-sec-0007"> <h3 class="title" id="CD012569-sec-0007">Authors' conclusions</h3> <p>For the treatment of hypertension, we have low certainty that renin inhibitors (RI) and angiotensin converting enzyme (ACE) inhibitors do not differ for all‐cause mortality and myocardial infarction. We have low to moderate certainty that they do not differ for adverse events. Small reductions in blood pressure with renin inhibitors compared to ACE inhibitors are of low certainty.  More independent, large, long‐term trials are needed to compare RIs with ACE inhibitors, particularly assessing morbidity and mortality outcomes, but also on blood pressure‐lowering effect.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012569-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012569-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012569-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012569-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012569-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012569-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012569-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012569-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012569-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012569-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012569-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012569-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012569-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012569-abs-0002" lang="en"> <h3>How renin inhibitors (RIs) compare with angiotensin converting enzyme (ACE) inhibitors for treating hypertension </h3> <p><b>Review question</b> </p> <p>We determined how renin inhibitors (RIs) compared with angiotensin converting enzyme (ACE) inhibitors for treating hypertension. </p> <p><b>Background</b> </p> <p>Hypertension is a worldwide public‐health challenge associated with high levels of occurrence and risks of circulatory and kidney disease. RIs were introduced into clinical use for hypertension in 2007. ACE inhibitors are widely prescribed for hypertension. However, the comparative effectiveness and safety of RIs and ACE inhibitors is not known. </p> <p><b>Search date</b> </p> <p>We searched for evidence up to August 2020.</p> <p><b>Study characteristics</b> </p> <p>We included randomized, active‐controlled, double‐blinded studies (RCTs) for this review. We include 11 RCTs involving 13,627 participants, with an average age from 51 to 74 years. Length of follow‐up ranged from four weeks to 36 months. </p> <p><b>Key results and certainty of evidence</b> </p> <p>Low‐certainty evidence showed no difference between RIs and ACE inhibitors for deaths from any cause, for heart attacks, for serious side effects or for leaving the study because of side effects. Low‐certainty evidence suggested that RIs reduce blood pressure more than ACE inhibitors do, but this could have been due to bias in the design and conduct of the studies. More independent RCTs are needed to assess illnesses and deaths, and to see if the difference in blood pressure‐lowering is real.   </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012569-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012569-sec-0063"></div> <h3 class="title" id="CD012569-sec-0064">Implications for practice</h3> <section id="CD012569-sec-0064"> <p>Head‐to‐head comparisons of renin inhibitors (RIs) and angiotensin converting enzyme (ACE) inhibitors for primary hypertension show no difference for all‐cause mortality or myocardial infarction (low‐certainty evidence).<br/>RIs were similar to ACE inhibitors for adverse events (moderate‐certainty evidence), serious adverse events and withdrawals due to adverse events (low‐certainty evidence). </p> <p>RIs were found to reduce systolic and diastolic blood pressure by a small amount more compared to ACE inhibitors (low‐certainty evidence), but that may be due to publication and source‐of‐funding bias.  </p> </section> <h3 class="title" id="CD012569-sec-0065">Implications for research</h3> <section id="CD012569-sec-0065"> <p>Most of the data in this review come from short‐term trials and subgroup data. Many of the included studies aimed at comparing the BP‐lowering effect of interventions within a few weeks are not prolonged enough to observe events such as death or cardiovascular events, etc. </p> <p>More large long‐term trials are needed to compare renin inhibitors with angiotensin converting enzyme (ACE) inhibitors, particularly for outcomes such as heart rate, cardiovascular events (heart failure, stroke, etc.) and end‐stage renal disease. </p> <p>Further independent short‐term double‐blinded RCTs are needed to determine whether there are blood pressure‐lowering differences between renin inhibitors and ACE inhibitors.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012569-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012569-sec-0008"></div> <div class="table" id="CD012569-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Renin inhibitors compared to ACE inhibitors for primary hypertension</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Renin inhibitors compared to ACE inhibitors for primary hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with primary hypertension<br/><b>Setting:</b> ambulatory clinics<br/><b>Intervention:</b> Renin inhibitors<br/><b>Comparison:</b> ACE inhibitors </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ACE inhibitors</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with Renin inhibitors</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow‐up: range 4 weeks to 36.6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5962<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.93 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1,000<br/>(9 fewer to 24 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal or non‐fatal myocardial infarction<br/>follow‐up: range 8 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>957<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.22 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/>(5 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6007<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.93 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 fewer per 1000<br/>(34 fewer to 15 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal or non‐fatal serious adverse events<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6007<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/>(0.89 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 more per 1000<br/>(3 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse effects (WDAE)<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6008<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.68 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 fewer per 1000<br/>(19 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBP<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5001<br/>(9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.72 mm Hg lower<br/>(2.47 lower to 0.97 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DBP<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5001<br/>(9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.18 lower<br/>(1.65 lower to 0.72 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% </p> <p>CI).<br/><br/><b>CI:</b> Confidence interval; <b>DBP:</b> diastolic blood pressure; <b>RR:</b> Risk ratio; <b>SBP:</b> systolic blood pressure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to high risk of source of funding bias.<br/><sup>b</sup>Results almost entirely from <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>, 60% hypertensive heart‐failure participants at baseline.<br/><sup>c</sup>Downgraded due to wide confidence interval.<br/><sup>d</sup>Downgraded due to risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012569-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012569-sec-0009"></div> <section id="CD012569-sec-0010"> <h3 class="title" id="CD012569-sec-0010">Description of the condition</h3> <p>Hypertension is an important worldwide public‐health challenge associated with high frequency and concomitant risks of cardiovascular and kidney disease. An estimated 29.8% of the world's adult population had hypertension in 2010 (<a href="./references#CD012569-bbs2-0044" title="MillsKT , BundyJD , KellyTN , ReedJE , KearneyPM , ReynoldsK , et al. Global burden and control of hypertension in 2010: Analysis of population-based studies from 89 countries. Circulation. Conference: American Heart Association's Epidemiology and Prevention/Lifestyle and Cardiometabolic Health 2015 Scientific Sessions Baltimore, MD United States2015;131:not stated.">Mills 2015</a>). Despite considerable improvement in raising awareness, treatment and control of hypertension, undiagnosed and uncontrolled hypertension among minority groups remains a challenge (<a href="./references#CD012569-bbs2-0029" title="EganBM , LiJ , ShatatIF , FullerJM , SinopoliA . Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation2014;129(20):2052-61.">Egan 2014</a>). </p> </section> <section id="CD012569-sec-0011"> <h3 class="title" id="CD012569-sec-0011">Description of the intervention</h3> <p>Orally‐active renin inhibitors (RIs) were developed in the 1980s, and one such drug, aliskiren, was introduced into clinical use for treatment of hypertension in 2007 (<a href="./references#CD012569-bbs2-0045" title="MusiniVM , LawrenceKA , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]">Musini 2017</a>). Angiotensin converting enzyme (ACE) inhibitors are widely prescribed for the treatment of primary hypertension (<a href="./references#CD012569-bbs2-0051" title="WangZ , WangX , ChenZ , WangW , ZhuH , ChenW , et al. Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns. American Journal of Hypertension2014;27(2):252-9.">Wang 2014</a>). </p> </section> <section id="CD012569-sec-0012"> <h3 class="title" id="CD012569-sec-0012">How the intervention might work</h3> <p>Excessive activation of the renin‐angiotensin system (RAS) has long been known to be associated with the pathophysiology of hypertension (<a href="./references#CD012569-bbs2-0035" title="FerrarioCM . Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension. An overview. Drugs1990;39(Suppl 2):1-8.">Ferrario 1990</a>). ACE inhibitors and RIs inhibit the RAS but have different sites of action; ACE inhibitors inhibit the conversion of angiotensin I to angiotensin II, while the RIs block enzymatic action of renin, the conversion of angiotensinogen to angiotensin I. </p> <p>Although pharmacologic manipulation of the RAS with ACE inhibitors has proven effective in the treatment of hypertension and related end‐organ damage, it provides only partial protection from disease progression (<a href="./references#CD012569-bbs2-0031" title="EnnezatPV , BerlowitzM , SonnenblickEH , Le JemtelTH . Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Current Cardiology Reports2000;2(3):258-62. [PMID: 10980901]">Ennezat 2000</a>). This might be attributable to the limitations of ACE inhibitors. Possible mechanisms for the limitations include firstly, interruption of negative feedback of renin release and a compensatory increase in renin and angiotensin I levels, which can overcome ACE inhibition; or secondly, the production of angiotensin II by non‐ACE pathways (<a href="./references#CD012569-bbs2-0032" title="EpsteinBJ , LeonardPT , ShahNK . The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond. Expert Review of Cardiovascular Therapy2012;10(6):713-25.">Epstein 2012</a>). ACE inhibitors also potentiate bradykinin levels, which are associated with cough and angioneurotic edema (<a href="./references#CD012569-bbs2-0046" title="NussbergerJ , CugnoM , AmstutzC , CicardiM , PellacaniA , AgostoniA . Plasma bradykinin in angio-oedema. Lancet1998;351(9117):1693-7.">Nussberger 1998</a>). </p> <p>Renin controls the first and rate‐limiting step in the activation of the RAS. By decreasing plasma renin activity and inhibiting the conversion of angiotensinogen to angiotensin I, it has been proposed that RIs might provide a more effective means of blocking the RAS (<a href="./references#CD012569-bbs2-0050" title="SkeggsLT , KahnJR , LentzK , ShumwayNP . The preparation, purification, and amino acid sequence of a polypeptide renin substrate. Journal of Experimental Medicine1957;106(3):439-53.">Skeggs 1957</a>). </p> </section> <section id="CD012569-sec-0013"> <h3 class="title" id="CD012569-sec-0013">Why it is important to do this review</h3> <p>Guidelines, such as <a href="./references#CD012569-bbs2-0033" title="WilliamsB , ManciaG , SpieringW , AgabitiRE , AziziM , BurnierM , et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension2018;36(10):1953-2041. [DOI: 10.1097/HJH.0000000000001940]">ESC/ESH 2018</a> and <a href="./references#CD012569-bbs2-0040" title="JamesPA , OparilS , CarterBL , CushmanWC , Dennison-HimmelfarbC , HandlerJ , et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014;311(5):507-20.">JNC8 2014</a>, recommend ACE inhibitors as first‐line therapy for hypertension, while the position of RIs in hypertension pharmacotherapy is still unclear. Recent meta‐analyses have shown that RIs have a favorable tolerability profile in people with mild‐to‐moderate hypertension (<a href="./references#CD012569-bbs2-0052" title="WeirMR , BushC , AndersonDR , ZhangJ , KeefeD , SatlinA . Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Journal of the American Society of Hypertension2007;1(4):264-77.">Weir 2007</a>; <a href="./references#CD012569-bbs2-0053" title="WhiteWB , BresalierR , KaplanAP , PalmerBF , RiddellRH , LesogorA , et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. Journal of Clinical Hypertension2010;12(10):765-75.">White 2010</a>). Moreover, a Cochrane Review has demonstrated that RIs reduce blood pressure (BP) more than placebo, and that the magnitude of this effect is similar to that for ACE inhibitors (<a href="./references#CD012569-bbs2-0037" title="HeranBS , WongMM , HeranIK , WrightJM . Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2008, Issue 3. Art. No: CD003823. [DOI: 10.1002/14651858.CD003823.pub2]">Heran 2008</a>; <a href="./references#CD012569-bbs2-0045" title="MusiniVM , LawrenceKA , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]">Musini 2017</a>). However, a drug's efficacy in lowering blood pressure cannot be considered as a definitive indicator of its effectiveness in reducing mortality and morbidity. To investigate the effectiveness and safety of renin inhibitors compared to ACE inhibitors, the most reliable method is head‐to‐head RCTs. </p> <p>We have published a Cochrane Review evaluating the benefits and harms of first‐line RAS inhibitors as an overall group compared to other first‐line antihypertensive drugs, and have shown that RAS inhibitors reduce adverse cardiovascular events more than calcium channel blockers and beta blockers (<a href="./references#CD012569-bbs2-0054" title="XueH , LuZ , TangWL , PangLW , WangGM , WongGW , et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD008170. [DOI: 10.1002/14651858.CD008170.pub2]">Xue 2015</a>). There is a Cochrane Review comparing angiotensin receptor blockers (ARBs) to ACE inhibitors (<a href="./references#CD012569-bbs2-0042" title="LiEC , HeranBS , WrightJM . Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD009096. [DOI: 10.1002/14651858.CD009096.pub2]">Li 2014</a>). However, there is currently no Cochrane Review comparing the effectiveness and safety of RIs with ACE inhibitors. This review therefore aims to compare RIs with ACE inhibitors for their effects on mortality and morbidity, and for their safety profiles in people with primary hypertension. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012569-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012569-sec-0014"></div> <p>To evaluate the efficacy and safety of renin inhibitors compared to ACE inhibitors in people with primary hypertension. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012569-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012569-sec-0015"></div> <section id="CD012569-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012569-sec-0017"> <h4 class="title">Types of studies</h4> <p>Studies must be double‐blind randomized controlled trials (DBRCTs) with a parallel design, randomizing participants to the renin inhibitor group or the ACE inhibitor group, and must have a duration of at least four weeks. </p> </section> <section id="CD012569-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with primary hypertension, and excluded people with proven secondary hypertension. </p> <p>Diagnostic criteria for primary hypertension:</p> <p> <ul id="CD012569-list-0001"> <li> <p>Office blood pressure (BP): systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg, or both.</p> </li> <li> <p>Ambulatory BP: daytime systolic BP ≥ 135 mmHg or diastolic BP ≥ 85 mmHg, or both; night‐time systolic BP ≥ 120 mmHg or diastolic BP ≥ 70 mmHg, or both; 24‐hour systolic BP ≥ 130 mmHg or diastolic BP ≥ 80 mmHg, or both. </p> </li> </ul> </p> </section> <section id="CD012569-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Invervention: any renin inhibitor. These include: aliskiren, ciprokiren, ditekiren, enalkiren, remikiren, rasilez, tekturna, terlakiren and zankiren. </p> <p>Control: any ACE inhibitor. These include: alacepril, altiopril, benazepril, captopril, ceranapril, ceronapril, cilazapril, deacetylalacepril, delapril, derapril, enalapril, enalaprilat, epicaptopril, fasidotril, fosinopril, foroxymithine, gemopatrilat, idapril, imidapril, indolapril, libenzapril, lisinopril, moexipril, moveltipril, omapatrilat, pentopril, perindopril, pivopril, quinapril, ramipril, rentiapril, s‐nitrosocaptopril, spirapril, temocapril, teprotide, trandolapril, utibapril, zabicipril, and zofenopril. </p> </section> <section id="CD012569-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Mortality and morbidity outcomes (see below) are considered most important.  Change in blood pressure is less important.   </p> <section id="CD012569-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012569-list-0002"> <li> <p>All‐cause mortality</p> </li> <li> <p>Total cardiovascular events:</p> <ul id="CD012569-list-0003"> <li> <p>fatal or non‐fatal myocardial infarction</p> </li> <li> <p>fatal or non‐fatal stroke</p> </li> <li> <p>fatal congestive heart failure</p> </li> <li> <p>hospitalizations for congestive heart failure</p> </li> </ul> </li> <li> <p>End‐stage renal disease (ESRD) </p> </li> <li> <p>Withdrawal due to adverse effects (WDAE)</p> </li> <li> <p>Fatal or non‐fatal serious adverse events (SAEs)</p> </li> <li> <p>Adverse events (AEs)</p> </li> </ul> </p> </section> <section id="CD012569-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012569-list-0004"> <li> <p>Individual cardiovascular events</p> </li> <li> <p>Change in systolic and diastolic BP</p> </li> <li> <p>Change in heart rate</p> </li> </ul> </p> </section> </section> </section> <section id="CD012569-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012569-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Hypertension Information Specialist searched the following databases from date of inception for published, unpublished, and ongoing studies: </p> <p> <ul id="CD012569-list-0005"> <li> <p>the Cochrane Hypertension Specialized Register via the Cochrane Register of Studies (searched 5 August 2020); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL 2020, Issue 7) via the Cochrane Register of Studies (searched 5 August 2020); </p> </li> <li> <p>MEDLINE Ovid (from 1946 onwards), MEDLINE Ovid Epub Ahead of Print, and MEDLINE Ovid In‐Process &amp; Other Non‐Indexed Citations (searched 5 August 2020); </p> </li> <li> <p>Embase Ovid (from 1974 onwards; searched 4 August 2020);</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 4 August 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.it.trialsearch" target="_blank">www.who.it.trialsearch</a>; searched 5 August 2020). </p> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomized controlled (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 6.1.0 (<a href="./references#CD012569-bbs2-0041" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). The Cochrane Collaboration, 2020. Available from www.training.cochrane.org/handbook.">Lefebvre 2020</a>)). We present search strategies for major databases in <a href="./appendices#CD012569-sec-0069">Appendix 1</a>. We have combined searches for this review with the related review <i>Renin inhibitors versus angiotensin receptor blockers for primary hypertension</i>. </p> </section> <section id="CD012569-sec-0025"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD012569-list-0006"> <li> <p>The Hypertension Information Specialist searched the Hypertension Specialized Register segment (which includes searches of MEDLINE and Epistemonikos for systematic reviews) to retrieve published systematic reviews related to this review title, so that we could scan their reference lists to identify additional relevant trials. </p> </li> <li> <p>We checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. </p> </li> <li> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of hypertension. We will consider adverse effects described in included studies only. </p> </li> </ul> </p> </section> </section> <section id="CD012569-sec-0026"> <h3 class="title" id="CD012569-sec-0026">Data collection and analysis</h3> <section id="CD012569-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GMW and LJL) independently examined the titles and abstracts of citations identified by the electronic searches for possible inclusion. We retrieved full‐text publications of potentially relevant studies and two review authors (GMW and LJL) then independently determined study eligibility. We resolved disagreements about study eligibility by discussion and, if necessary, a third review author (WLT) would arbitrate. </p> </section> <section id="CD012569-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (GMW and LJL) independently extracted data using a standard form, and then cross‐checked. A third review author (WLT) confirmed all numeric calculations and graphic interpolations. We resolved any discrepancies by consensus. </p> </section> <section id="CD012569-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The review authors (GMW and LJL) independently used the Cochrane 'Risk of bias' tool to categorize studies as having low, unclear, or high risk of bias for sequence generation, allocation sequence concealment, loss of blinding, selective reporting, incomplete reporting of outcomes, and other potential sources of bias (<a href="./references#CD012569-bbs2-0038" title="HigginsJP , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD012569-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We based quantitative analysis of outcomes on intention‐to‐treat principles when possible. For dichotomous outcomes, we expressed results as a risk ratio (RR) with a 95% confidence interval (CI). For combining continuous variables, we used the mean difference (MD) with a 95% CI, whereby the studies are weighted according to the number of participants in the study and the within‐study variance. </p> </section> <section id="CD012569-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual trial. For trials having more than two arms, we only included arms relevant to this review. Where studies included more than one intervention group with a single comparator arm, we included both intervention groups. </p> </section> <section id="CD012569-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If the included studies had information missing, we contacted investigators (using email, letter or fax) to obtain the missing information. When studies did not report a within‐study variance for the effect change of continuous data, we imputed the standard deviation (SD) using the following hierarchy: </p> <p> <ul id="CD012569-list-0007"> <li> <p>Pooled SD calculated either from the t‐statistic corresponding to an exact P value reported, or from the 95% CI of the mean difference between treatment group and comparative group; </p> </li> <li> <p>SD at the end of treatment;</p> </li> <li> <p>SD at baseline;</p> </li> <li> <p>Weighted mean SD of change calculated from at least three other trials using the same class of drug (at any dose). </p> </li> </ul> </p> </section> <section id="CD012569-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered a P value of 0.10 or less from the Chi<sup>2</sup> test as statistically significant for heterogeneity (<a href="./references#CD012569-bbs2-0028" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). The Cochrane Collaboration, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). We also used the I<sup>2</sup> statistic for quantifying inconsistency across studies, following the rough guide to interpretation as described in <a href="./references#CD012569-bbs2-0028" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). The Cochrane Collaboration, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>: </p> <p> <ul id="CD012569-list-0008"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD012569-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to investigate publication reporting bias when suspected. As a rule of thumb, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in the meta‐analysis, because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry. </p> </section> <section id="CD012569-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We conducted data synthesis and analyses using Cochrane Review Manager 5 software (<a href="./references#CD012569-bbs2-0047" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We describe data results in tables and forest plots. We also give full details of all studies we include and exclude. </p> <p>Where we identify statistically significant heterogeneity, we use a random‐effects model for meta‐analysis. Since a random‐effects model can overemphasize smaller studies, we planned a sensitivity analysis to gauge the effects of using a random‐effects model versus a fixed‐effect model on the observed intervention effect. </p> </section> <section id="CD012569-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If appropriate, we would perform subgroup analyses.</p> <p>Heterogeneity among participants could be related to: gender, age, baseline blood pressure, high‐risk participants, participants with comorbid conditions, or participants with a previous history of cardiovascular morbidity and renal disease. </p> <p>Heterogeneity in treatments could be related to: form of drugs, dosage of drugs, or duration of therapy. </p> </section> <section id="CD012569-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>If appropriate, we would test the robustness of the results using several sensitivity analyses, including: </p> <p> <ul id="CD012569-list-0009"> <li> <p>Trials that were industry‐sponsored versus non‐industry sponsored;</p> </li> <li> <p>Trials with reported standard deviations of effect change versus imputed standard deviations; </p> </li> <li> <p>Trials that have a high risk of bias versus those with a low risk of bias.</p> </li> </ul> </p> </section> <section id="CD012569-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach (<a href="./references#CD012569-bbs2-0036" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed before October 2020). Available at gradepro.org.">GRADEpro GDT</a>) to assess the quality of the supporting evidence behind each estimate of treatment effect (<a href="./references#CD012569-bbs2-0048" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al (editors). Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. available from www.cochrane-handbook.org.">Schünemann 2011b</a>; <a href="./references#CD012569-bbs2-0049" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al Schünemann HJ, OxmanAD , HigginsJPT , VistGE , GlasziouP , Guyatt GH (editors). Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). The Cochrane Collaboration, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>). We presented key findings of the review, including a summary of the amount of data, the magnitude of the effect size and the overall certainty of the evidence, in <a href="./full#CD012569-tbl-0001">summary of findings Table 1</a>. We had preselected the following outcomes for inclusion in <a href="./full#CD012569-tbl-0001">summary of findings Table 1</a>: </p> <p> <ul id="CD012569-list-0010"> <li> <p>All‐cause mortality</p> </li> <li> <p>Total cardiovascular events*:</p> <ul id="CD012569-list-0011"> <li> <p>fatal or non‐fatal myocardial infarction</p> </li> <li> <p>fatal or non‐fatal stroke*</p> </li> <li> <p>fatal congestive heart failure*</p> </li> <li> <p>hospitalizations for congestive heart failure*</p> </li> </ul> </li> <li> <p>End‐stage renal disease (ESRD)* </p> </li> <li> <p>Withdrawal due to adverse effects (WDAE)</p> </li> <li> <p>Fatal or non‐fatal serious adverse events</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Systolic blood pressure (SBP)</p> </li> <li> <p>Diastolic blood pressure (DBP)</p> </li> </ul> </p> <p>*These outcomes were not shown in the 'Summary of findings' table, due to no data available. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012569-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012569-sec-0039"></div> <section id="CD012569-sec-0040"> <h3 class="title">Description of studies</h3> <p>We include 11 studies (15 publications). Nine trials reported BP data; 10 trials reported adverse events (AEs), serious adverse events (SAEs) and withdrawals due to adverse events (WDAEs); five trials reported all‐cause mortality events, and two trials reported fatal or nonfatal myocardial infarction. None of the trials reported total cardiovascular events (myocardial infarction, stroke, congestive heart failure, and hospitalizations for heart failure), hospitalizations for heart failure, stroke, ESRD or change in heart rate. </p> <section id="CD012569-sec-0041"> <h4 class="title">Results of the search</h4> <p>The results of the search are shown in the PRISMA diagram (<a href="#CD012569-fig-0001">Figure 1</a>). Our search revealed 3079 references, which were reduced to 2136 after de‐duplication. After screening titles and abstracts, we obtained 30 full‐text articles. Of these articles, we excluded 14 studies (15 articles) based on them not meeting our inclusion criteria. </p> <div class="figure" id="CD012569-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012569-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012569-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD012569-sec-0078" title="">Characteristics of included studies</a> for details. </p> <p>We include 11 RCTs involving 13,627 participants that were randomized (the total number is different from the sum of numbers of participants given in the meta‐analyses form, due to a subtraction of irrelevant groups from trials). Although aimed at people with heart failure, <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a> was included because over 60% of its participants had hypertension at baseline, and it reported all‐cause mortality data for the hypertension subgroup which contributed to our meta‐analysis. </p> <p>The mean follow‐up of the 11 RCTs ranged from four weeks to 36.6 months. The four trials with the longest duration were: <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a> (36.6 months), <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a> (54 weeks), <a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a> (36 weeks) and <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a> (26 weeks). Most of the RCTs were conducted at multiple centers in various geographic locations (North America, Europe, Asia): <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>, 789 centers in 43 countries; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>, 115 centers in seven countries; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>, 80 centers worldwide; <a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. ">Palatini 2010</a>, 97 centers worldwide; <a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>, 62 centers worldwide; <a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. ">Uresin 2007</a>, 125 centers worldwide. </p> <p>The average age of participants ranged from 51.5 years (<a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>) to 74.2 years (<a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>), with an approximately equal number of women in each arm of the various  trials. The mean baseline blood pressure of participants in studies ranged from 146/93 mmHg (<a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. ">Palatini 2010</a>) to 166/91 mmHg (<a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. ">ALIAS 2012</a>). Data obtained were therefore from mild‐to‐moderate hypertension participants. Two RCTs were aimed at hypertensive participants with specific diseases (as inclusion criteria): one targeted chronic heart failure (<a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>), and the other type 1 or 2 diabetes mellitus (<a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. ">Uresin 2007</a>). In addition, some of the participants (7% to 58.6%) in several RCTs had co‐morbidities such as diabetes or metabolic syndrome at baseline (<a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. ">Strasser 2007</a>; <a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>; <a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. ">Zhu 2012</a>). See <a href="#CD012569-tbl-0002">Table 1</a> for more detail. </p> <div class="table" id="CD012569-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean Age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Co‐morbidity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Add‐on drugs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline SBP/DBP (mm Hg)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. "><b>AGELESS 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 72.0</p> <p>C: 72.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 21.7%; ramipril 19.6%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150‐300 mg/day</p> <p>C: Ramipril 5‐10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 12.5 ‐ 25 mg/day or</p> <p>HCTZ 12.5 ‐ 25 mg/day +amlodipine 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 156.5/85.5</p> <p>C: 156.6/86.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. "><b>ALIAS 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 60.1</p> <p>C: 59.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150‐300 mg/day</p> <p>C: Ramipril 5‐10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 166.4/89.9</p> <p>C: 166.3/90.9</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. "><b>Andersen 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 53.4</p> <p>C: 53.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 10%; ramipril 11.6%.</p> <p>Baseline metabolic syndrome: aliskiren 40.7%; ramipril 43.3%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C: Ramipril 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 12.5 ‐ 25 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 151.3/98.8</p> <p>C: 151.4/98.9</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. "><b>ATMOSPHERE 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 63.3</p> <p>C1: 63.3</p> <p>C2: 63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heart failure as inclusion criterion;</p> <p>Baseline diabetes: aliskiren 26.8%;</p> <p>enalapril 27.9%; enalapril + aliskiren 28.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C1: Enalapril 5 ‐ 10 mg/day</p> <p>C2: Enalapril 5 ‐ 10 mg/day + Aliskiren 150 ‐ 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optimal heart failure therapy, including beta blockers, but with the exception of ACE inhibitors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p>Note: Numbers of</p> <p>hypertensive</p> <p>participants at baseline, n(%):</p> <p>T: 1460 (62.4%)</p> <p>C1: 1425 (61.0%)</p> <p>C2: 1447 (61.8%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]"><b>Jones‐Burton 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 52.8</p> <p>T2: 52.8</p> <p>C1: 51.5</p> <p>C2: 53.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1:MK‐8141 250 mg/day</p> <p>T2:MK‐8141 500 mg/day</p> <p>C1: Enalapril 20 mg/day</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 150.2/93.8</p> <p>T2: 149.7/94.2</p> <p>C1: 150.6/95.1</p> <p>C2: 151.9/93.6</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). "><b>NCT00631917 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 59.3</p> <p>C: 59.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 22.1%; ramipril 25.1%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C: Ramipril 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 12.5 ‐ 25 mg/day or HCTZ 12.5 ‐ 25 mg/ay + amlodipine 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. "><b>Palatini 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 53.5</p> <p>C1: 53.9</p> <p>C2: 53.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C1: Ramipril 5 ‐ 10 mg/day</p> <p>C2: Irbesartan 150 ‐ 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 145.5/93</p> <p>C1:145.8/92.4</p> <p>C2:145.4/93.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. "><b>Strasser 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 55.3</p> <p>C: 55.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 12.0%; lisinopril 13.8%.</p> <p>Baseline metabolic syndrome: aliskiren 52.8%; lisinopril 58.6%</p> <p>Baseline hypercholesterolemia: aliskiren 16.8%; lisinopril 15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C: Lisinopril 20 ‐ 40 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 25 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 163.4/108.4</p> <p>C: 161.7/108.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. "><b>Uresin 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 60.0</p> <p>C1: 59.9</p> <p>C2: 59.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type 1 or 2 diabetes mellitus as inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C1: Ramipril 5 ‐ 10 mg/day</p> <p>C2: Aliskiren 150 ‐ 300 mg/day+ Ramipril 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 157.4/98.4</p> <p>C1: 155.9/98.2</p> <p>C2: 156.5/98.4</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. "><b>Verdecchia 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 73.6</p> <p>T2: 73.2</p> <p>T3: 73.0</p> <p>C: 74.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 75 mg 13.2%; aliskiren 150 mg 11.9%; aliskiren 300 mg 11.7%; lisinopril 7.0% </p> <p>Baseline metabolic syndrome: aliskiren 75 mg 27.5%; aliskiren 150 mg 22.6%; aliskiren 300 mg 24.5%; lisinopril 23.3% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: Aliskiren 75 mg/day</p> <p>T2: Aliskiren 150 mg/day</p> <p>T3: Aliskiren 300 mg/day</p> <p>C: Lisinopril 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 160.4/88.0</p> <p>T2: 160.2/89.3</p> <p>T3: 160.7/90.1</p> <p>C: 161.4/88.1</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. "><b>Zhu 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 52.7</p> <p>T2: 53.3</p> <p>T3: 53.8</p> <p>C: 52.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 75 mg 10.5%;</p> <p>aliskiren 150 mg 9.6%;</p> <p>aliskiren 300 mg 10.9%;</p> <p>ramipril 5 mg 15.2%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: Aliskiren 75 mg/day</p> <p>T2: Aliskiren 150 mg/day</p> <p>T3: Aliskiren 300 mg/day</p> <p>C: Ramipril 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 147.3/98.9</p> <p>T2: 146.8/98.5</p> <p>T3: 148.9/98.9</p> <p>C1: 148.5/98.8</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>C: control group; DBP: diastolic blood pressure; HCTZ: hydrochlorothiazide; N: total number of participants randomized in each trial; T: test group; NA: not available; SBP: systolic blood pressure </p> </div> </div> <p>ACE inhibitors included enalapril (<a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>; <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>), lisinopril (<a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>) and ramipril (<a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. ">ALIAS 2012</a>; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. ">Uresin 2007</a>). RIs included MK‐8141 (<a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>) and aliskiren (all other trials). Four RCTs allowed hydrochlorothiazide or amlodipine or both as add‐on medications to their treatment regimen in order to control BP (<a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. ">Strasser 2007</a>). Three studies had multiple‐dose groups for RIs. <a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a> had two arms of MK‐8141 at dose 250 mg/day and 500 mg/day respectively. <a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a> and <a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. ">Zhu 2012</a> both had three arms of aliskiren at dose 75, 150 and 300 mg/day respectively. We combined the data from different dose RIs groups from those studies to create a single pair‐wise comparison. </p> </section> <section id="CD012569-sec-0043"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD012569-sec-0079" title="">Characteristics of excluded studies</a> for details. </p> <p>We have excluded two potentially eligible studies in the phase of full‐text review, since no information on hypertensive participants was provided (<a href="./references#CD012569-bbs2-0014" title="ESCAPE-SHF: A double-blind, double-dummy, randomized, multicenter, parallel group study to evaluate the effects of aliskiren, ramipril and combination treatment on plasma concentration of angiotensin II in patients with decompensated systolic heart failure. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=5123 (accessed 11 October 2020). ">ESCAPE‐SHF 2011</a>; <a href="./references#CD012569-bbs2-0017" title="KiowskiW , BeermannJ , RickenbacherP , HaemmerliR , ThomasM , BurkartF , et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation1994;90(6):2748-56. ">Kiowski 1994</a>). However, we included <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a> in our analyses because it reported all‐cause mortality data on the hypertensive subgroup. Four studies did not report outcomes pertinent to this review (<a href="./references#CD012569-bbs2-0012" title="AziziM , GuyeneTT , Chatellier G, MenardJ . Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. Journal of Hypertension1994;12(4):419-27. ">Azizi 1994</a>; <a href="./references#CD012569-bbs2-0013" title="BurnierM , BredeY , LowyA . Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.. International Journal of Clinical Practice2011;65(2):127-33. ">Burnier 2011</a>; <a href="./references#CD012569-bbs2-0015" title="FisherND , AllanD , KiforI , GabouryCL , WilliamsGH , MooreTJ , et al. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension1994;23(1):44-51. ">Fisher 1994</a>; <a href="./references#CD012569-bbs2-0023" title="TsygankovaOV , PlatonovD , BondarevaZG , ArutyunyanIV . Do early and late nephroprotective effects differ with different inhibitors of renin-angiotensin-aldosteron system in chronic heart failure patients?European Heart Journal2012;33:808-9. ">Tsygankova 2012</a>). Three studies were not parallel design (<a href="./references#CD012569-bbs2-0015" title="FisherND , AllanD , KiforI , GabouryCL , WilliamsGH , MooreTJ , et al. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension1994;23(1):44-51. ">Fisher 1994</a>; <a href="./references#CD012569-bbs2-0019" title="LizakowskiS , TylickiL , RenkeM , RutkowskiP , HeleniakZ , Slawinska-MorawskaM , et al. Aliskiren and perindopril reduce the levels of transforming growth factor-beta in patients with non-diabetic kidney disease. American Journal of Hypertension2012;25(6):636-9. LizakowskiS , TylickiL , RenkeM , RutkowskiP , HeleniakZ , Slawinska-MorawskaM , et al. Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial. International Urology and Nephrology2012;44(6):1763-70. ">Lizakowski 2012</a>; <a href="./references#CD012569-bbs2-0022" title="QuinnU , BrownC , MaguireB , McAdamB , StantonAV . Significantly greater ambulatory BP lowering in high renin hypertensive patients with high-dose angiotensin receptor blockade than with ACE-inhibition or direct renin inhibition. Journal of Human Hypertension2010;24(10):688. ">Quinn 2010</a>), and three studies were not blinded (<a href="./references#CD012569-bbs2-0016" title="FogariR , MugelliniA , ZoppiA , PretiP , MaffioliP , PerroneT , et al. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. Expert Opinion on Pharmacotherapy2013;14(4):371-84. ">Fogari 2013</a>; <a href="./references#CD012569-bbs2-0020" title="MakówkaA , Olejniczak-FortakM , NowickiM . A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients - a pilot open label study. Kidney and Blood Pressure Research2012;36(1):18-25. ">Makówka 2012</a>; <a href="./references#CD012569-bbs2-0024" title="VirdisA , GhiadoniL , QasemAA , LorenziniG , DurantE , CartoniG , et al. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. European Heart Journal2012;33(12):1530-8. ">Virdis 2012</a>). One study (<a href="./references#CD012569-bbs2-0021" title="Novartis. A multicenter, double-blind, randomized, 52-week, extension study to evaluate the long term safety, tolerability and efficacy of aliskiren compared to enalapril in pediatric hypertensive patients 6-17 years of age. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=14549 2015 (accessed 11 October 2020). ">NCT01151410 2015</a>) was aimed at pediatric hypertension, and was excluded because the diagnostic criteria for pediatric hypertension differed from those for adults. In addition, <a href="./references#CD012569-bbs2-0025" title="ZeymerU , DechendR , DeegE , HagedornI , SchmiederR . Blood pressure reduction with aliskiren in outpatients with hypertension in real life during 2-year follow-up. Results of the prospective 3A Registry. European Heart Journal2012;33:773-4. ">Zeymer 2012</a> was excluded as a non‐interventional study. </p> </section> </section> <section id="CD012569-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD012569-sec-0078" title="">Characteristics of included studies</a> and 'Risk of bias' graph (<a href="#CD012569-fig-0002">Figure 2</a>) for more details. </p> <div class="figure" id="CD012569-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012569-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>All included studies were double‐blind randomized control trials at low or unclear risk of bias for allocation, blinding, incomplete outcome data and selective reporting, but with high risk of bias for other sources of bias. </p> <section id="CD012569-sec-0045"> <h4 class="title">Allocation</h4> <p>All included studies reported randomization, but four of them did not mention the sequence generation process (<a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. ">ALIAS 2012</a>; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. ">Zhu 2012</a>) and five of them did not provide information about method of allocation concealment (<a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. ">ALIAS 2012</a>; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. ">Zhu 2012</a>). In these studies, we deemed selection bias to be unclear. The baseline participant characteristics tables of these studies revealed no significant differences between study arms indicative of inadequate randomization. Seven RCTs (<a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>; <a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>; <a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. ">Palatini 2010</a>; <a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. ">Strasser 2007</a>; <a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. ">Uresin 2007</a>; <a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>) are at low risk of bias for the sequence generation process, because they reported adequate sequence generation using computer‐generated random numbers and validated interactive voice response systems that automate random assignment. Six RCTs (<a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>; <a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. ">Palatini 2010</a>; <a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. ">Strasser 2007</a>; <a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. ">Uresin 2007</a>; <a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>) have low risk of bias for allocation concealment, because they reported the use of a voice‐based computerized randomization system that involved concealed trial‐group assignments. </p> </section> <section id="CD012569-sec-0046"> <h4 class="title">Blinding</h4> <p>All included studies mentioned blinding, but seven of them (<a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. ">Palatini 2010</a>; <a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. ">Strasser 2007</a>; <a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>) reported using a double‐blind, double‐dummy design, so we deemed them to have a low risk of performance bias. Four studies (<a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. ">ALIAS 2012</a>; <a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>; <a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. ">Uresin 2007</a>; <a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. ">Zhu 2012</a>) have unclear risk of performance bias as information about blinding of participants and personnel was not provided. Three studies reported using blinding of outcome assessment (<a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. ">Strasser 2007</a>). For the remaining eight studies, it was unclear whether outcome assessors were blinded from the time of randomization until release of database lock, so we deemed them to be at unclear risk of detection bias. </p> </section> <section id="CD012569-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Missing data had been imputed using appropriate methods (intention‐to‐treat analysis), with participant demographics and characteristics at baseline similar between treatment groups in 10 studies, which we judged to be at low risk of attrition bias. One study (<a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>) accounted for participants lost to follow‐up, and missing data were unlikely to have an impact on the results of the trial. </p> </section> <section id="CD012569-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Although protocols were not available except for <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>, all studies reported all prespecified outcomes in their Methods, so we judged them as having a low risk of reporting bias. </p> </section> <section id="CD012569-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a> was jointly funded by Merck &amp; Co. Inc. and Actelion Pharmaceuticals Ltd. The authors are employees of Merck &amp; Co. Inc. and Actelion Pharmaceuticals Ltd. Novartis, (manufacturer of aliskiren) supported the other 10 trials. </p> <p>A Cochrane Review (<a href="./references#CD012569-bbs2-0043" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>) has found evidence that industry sponsorship is associated with more favorable results and conclusions, and that this bias is not captured by standard 'Risk of bias' assessments. We therefore rated all the included studies at high risk of bias, with concerns about methodology that might be influenced by vested interests. This is particularly true for the blood pressure outcome. </p> </section> </section> <section id="CD012569-sec-0050"> <h3 class="title" id="CD012569-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD012569-tbl-0001"><b>Summary of findings 1</b> Renin inhibitors compared to ACE inhibitors for primary hypertension</a> </p> <section id="CD012569-sec-0051"> <h4 class="title">All‐cause mortality</h4> <p>Five studies (5962 participants) reported all‐cause mortality (<a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>; <a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. ">Uresin 2007</a>). There was no difference between RIs and ACE inhibitors (risk ratio (RR) 1.05, 95% confidence interval (CI) 0.93 to 1.18; <a href="./references#CD012569-fig-0005" title="">Analysis 1.1</a>). There was no evidence of statistical heterogeneity across the trials included for this outcome (P value = 0.79; I<sup>2</sup> = 0%). </p> </section> <section id="CD012569-sec-0052"> <h4 class="title">Myocardial infarction</h4> <p>Two studies (957 participants) reported total myocardial infarction (<a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). ">NCT00631917 2011</a>; <a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. ">Strasser 2007</a>). There was no difference between RIs and ACE inhibitors (RR 0.86, 95% CI 0.22 to 3.39; <a href="./references#CD012569-fig-0006" title="">Analysis 1.2</a>). There was minimal statistical heterogeneity across the trials included for this outcome (P value = 0.21; I<sup>2</sup> = 36%). </p> </section> <section id="CD012569-sec-0053"> <h4 class="title">Adverse events</h4> <p>Pooling of the 10 studies (6007 participants) that reported adverse events showed no difference between RIs and ACE inhibitors (RR 0.98, 95% CI 0.93 to 1.03; <a href="./references#CD012569-fig-0007" title="">Analysis 1.3</a>). There was no significant heterogeneity across trials for this outcome (P value = 0.68, I<sup>2</sup> = 0%). Specific reasons for adverse events were available for all studies except one (<a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. ">ALIAS 2012</a>). </p> </section> <section id="CD012569-sec-0054"> <h4 class="title">Serious adverse events</h4> <p>Ten studies (6007 participants) reported on serious adverse events. We found no difference between RIs and ACE inhibitors (RR 1.21, 95% CI 0.89 to 1.64; <a href="./references#CD012569-fig-0008" title="">Analysis 1.4</a>). There was no significant heterogeneity across trials for this outcome (P value = 0.84, I<sup>2</sup> = 0%).<br/>  </p> </section> <section id="CD012569-sec-0055"> <h4 class="title">Withdrawals due to AEs</h4> <p>Ten studies (6008 participants) reported on withdrawals due to adverse events (WDAEs). There was no evidence of a difference between RIs and ACE inhibitors for WDAEs (RR 0.85, 95% CI 0.68 to 1.06; <a href="./references#CD012569-fig-0009" title="">Analysis 1.5</a>) with no significant heterogeneity (P value = 0.44, I<sup>2</sup> = 0%).<br/>  </p> </section> <section id="CD012569-sec-0056"> <h4 class="title">Blood pressure</h4> <p>Nine trials (5001 participants) reported BP data. RIs reduced both systolic blood pressure (SBP) (MD −1.72, 95% CI −2.47 to −0.97; <a href="./references#CD012569-fig-0010" title="">Analysis 1.6</a>) and diastolic blood pressure (DBP) (MD −1.18, 95% CI −1.65 to −0.72; <a href="./references#CD012569-fig-0011" title="">Analysis 1.7</a>) to a greater extent than ACE inhibitors. There was minimal statistical heterogeneity across trials for SBP (P value = 0.14, I<sup>2</sup> = 34%) or for DBP (P value = 0.13, I<sup>2</sup> = 36%). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012569-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012569-sec-0057"></div> <section id="CD012569-sec-0058"> <h3 class="title" id="CD012569-sec-0058">Summary of main results</h3> <p>This review demonstrates that RIs compared to ACE inhibitors have not been proven to be significantly different for the outcomes all‐cause mortality and myocardial infarction for people with mild‐to‐moderate hypertension. It should be noted that the data for mortality came almost entirely from a subgroup of the <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a> trial, in which all the participants had heart failure plus hypertension. No data were available for total cardiovascular events, hospitalizations for heart failure, stroke, end‐stage renal disease or change in heart rate. We therefore currently have low‐certainty evidence that RIs and ACE inhibitors do not differ for morbidity and mortality outcomes. </p> <p>There was no significant difference between RIs and ACE inhibitors for adverse events, serious adverse events or withdrawals due to adverse events. We have low‐to‐moderate certainty that RIs and ACE inhibitors are similar for tolerability outcomes. </p> <p>RIs appeared to reduce SBP and DBP on average more than ACE inhibitors. However, we have graded this finding as low certainty, as there was a high risk of publication bias and in particular source of funding bias for this outcome. </p> <p>We conducted subgroup analyses to investigate the effect on blood pressure of RIs versus different ACE inhibitors. The overall reduction in blood pressure with aliskiren was limited to the six RCTs comparing it with ramipril. There was no reduction in blood pressure when aliskiren was compared to lisinopril (one RCT) or to enalapril (two RCTs). </p> <p>All included studies were industry‐sponsored and had similar high risk of bias. The planned sensitivity analysis for industry sponsorship and risk of bias was therefore not possible. Studies with reported standard deviations of effect change yielded similar results for mean changes in systolic and diastolic BP. </p> </section> <section id="CD012569-sec-0059"> <h3 class="title" id="CD012569-sec-0059">Overall completeness and applicability of evidence</h3> <p>Participants in some of the included studies had no co‐morbidities. The data on all‐cause mortality were mainly derived from <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>, which included participants with chronic heart failure. Diabetes and metabolic syndrome were risk factors for participants in some of the included RCTs. This review therefore provides evidence for hypertensive people with or without co‐morbidities such as heart failure or diabetes and metabolic syndrome. </p> <p>The baseline blood pressures represented in the pooled population largely ranged from mild to moderate hypertension, with average mean baseline blood pressures ranging from 146/93 (SBP/DBP) mmHg (<a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. ">Palatini 2010</a>) to 166/91 (SBP/DBP) mmHg (<a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. ">ALIAS 2012</a>). Our analyses are therefore confined to people whose hypertension is in the mild‐to‐moderate range.  </p> <p>In terms of the drugs represented, most of the data are available for aliskiren, the only marketed renin inhibitor. For trials with multiple dose arms (<a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. ">Zhu 2012</a>; <a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]">Jones‐Burton 2010</a>; <a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>), we combined the data for each dose into a single arm. The results represented were therefore all doses taken together for aliskiren (75 mg to 300 mg) and for MK‐8141 (250 mg to 500 mg). For the ACE inhibitors, the analyses of primary and secondary outcomes included ramipril (5 mg to 10 mg), enalapril (2.5 mg to 40 mg) and lisinopril (10 mg to 40 mg). Our analyses were underpowered to differentiate the effects of different drugs and doses using subgroup analysis. </p> <p>For people using ACE inhibitors, it is known that a refractory dry cough can lead them to stop medication. In our analyses, RIs had no more adverse events, serious adverse events or WDAEs compared to ACE inhibitors. However, we note that several RCTs reported more cough in the ramipril arms than in the aliskiren arms (<a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. ">Andersen 2008</a>; <a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. ">AGELESS 2010</a>; <a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. ">Zhu 2012</a>). </p> <p>In this systematic review, we did not find any data on change in heart rate, total cardiovascular events (myocardial infarction, heart failure, stroke), stroke, heart failure or end‐stage renal disease. We need more and larger studies comparing RIs with ACE inhibitors for hypertension treatment. </p> <p>The results of this review are in line with current clinical guidelines for the initial drug treatment of hypertension that recommend agents that have been shown to reduce clinical events, including ACE inhibitors, angiotensin receptor blockers, thiazide diuretics and calcium channel blockers, with renin inhibitors as secondary agents (<a href="./references#CD012569-bbs2-0026" title="WheltonPK , CareyRM , AronowWS , CaseyDE , CollinsKJ , Dennison HimmelfarbC , et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and Mmnagement of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018, 2018;71(6):e13-e115. [DOI: 10.1161/HYP.0000000000000065]">ACC/AHA 2017</a>; <a href="./references#CD012569-bbs2-0039" title="UngerT , BorghiC , CharcharF , KhanNA , PoulterNR , PrabhakaranD , et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension2020;75(6):1334-57. [DOI: 10.1097/HJH.0000000000002453]">ISH 2020</a>; <a href="./references#CD012569-bbs2-0033" title="WilliamsB , ManciaG , SpieringW , AgabitiRE , AziziM , BurnierM , et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension2018;36(10):1953-2041. [DOI: 10.1097/HJH.0000000000001940]">ESC/ESH 2018</a>). </p> </section> <section id="CD012569-sec-0060"> <h3 class="title" id="CD012569-sec-0060">Quality of the evidence</h3> <p>See <a href="./full#CD012569-tbl-0001">summary of findings Table 1</a> for details. </p> <p>The included RCTs were double‐blind, and were at low to high risk of bias. We found no inconsistency across studies in any of the meta‐analyses. The trials contributing to this review were all funded by the manufacturer. Furthermore, we detected possible publication bias in funnel plots (see <a href="#CD012569-fig-0003">Figure 3</a> and <a href="#CD012569-fig-0004">Figure 4</a>), although only nine of the 11 RCTs were analyzed. It is therefore possible that the lower blood pressure with the renin inhibitors was achieved by preferentially publishing trials favoring the renin inhibitor. The certainty of evidence for the blood pressure outcomes were therefore downgraded to low, due to the high risk of publication bias and source‐of‐funding bias. </p> <div class="figure" id="CD012569-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.6 SBP." data-id="CD012569-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.6 SBP.</p> </div> </div> </div> <div class="figure" id="CD012569-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.7 DBP." data-id="CD012569-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.7 DBP.</p> </div> </div> </div> <p>For all‐cause mortality, we downgraded the certainty of evidence to low, because the result was dominated by a hypertensive subgroup of <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>.  For myocardial infarction, fatal or non‐fatal serious adverse events and WDAEs, we downgraded the certainty of evidence to very low to low, due to the wide confidence intervals. For adverse events, the certainty of evidence was graded as moderate. </p> </section> <section id="CD012569-sec-0061"> <h3 class="title" id="CD012569-sec-0061">Potential biases in the review process</h3> <p>We assumed that all doses of all drugs within each class for our outcomes of interest were equally effective. This could have biased the blood pressure results against aliskiren, as aliskiren has been shown to have a dose‐related BP‐lowering effect (<a href="./references#CD012569-bbs2-0045" title="MusiniVM , LawrenceKA , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]">Musini 2017</a>). With regard to safety, there was no evidence of an increased incidence of adverse events with increasing aliskiren dose (75 mg to 300 mg) (<a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. ">Verdecchia 2007</a>). However, <a href="./references#CD012569-bbs2-0045" title="MusiniVM , LawrenceKA , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]">Musini 2017</a> found a significant increase in diarrhea in the aliskiren 600 mg group; the U.S. Food and Drug Administration (FDA) have approved a revision of the aliskiren label to warn of this overdose risk (<a href="./references#CD012569-bbs2-0045" title="MusiniVM , LawrenceKA , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]">Musini 2017</a>). We did not conduct the subgroup analyses to adequately test this assumption, as it would have been underpowered. In addition, to maximize inclusiveness, we included studies with additional BP‐lowering medications (mainly hydrochlorothiazide, amlodipine, etc.) other than study drugs to control BP. We have assumed that this was balanced in each arm.  However, it is unknown whether the added BP‐lowering regimens would equally affect outcomes. Unfortunately, there were too few trials for the primary outcomes to assess publication bias. </p> </section> <section id="CD012569-sec-0062"> <h3 class="title" id="CD012569-sec-0062">Agreements and disagreements with other studies or reviews</h3> <p>This systematic review suggests that RIs reduce mean SBP and DBP more than ACE inhibitors, but as explained above we have low certainty for this finding.  In contrast, comprehensive Cochrane Reviews of placebo‐controlled data show that the magnitude of the BP‐lowering with RIs is similar to that for ACE inhibitors (<a href="./references#CD012569-bbs2-0037" title="HeranBS , WongMM , HeranIK , WrightJM . Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2008, Issue 3. Art. No: CD003823. [DOI: 10.1002/14651858.CD003823.pub2]">Heran 2008</a>; <a href="./references#CD012569-bbs2-0045" title="MusiniVM , LawrenceKA , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]">Musini 2017</a>). A non‐Cochrane review  (<a href="./references#CD012569-bbs2-0027" title="ChenY , MengL , ShaoH , YuF . Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. Hypertension Research2013;36(3):252-61. [DOI: 10.1038/hr.2012.185]">Chen 2013</a>) suggested that aliskiren reduced SBP  by a similar amount as ACE inhibitors, but reduced DBP more than ACE inhibitors. More independent trials are needed to establish the weight of evidence. </p> <p>Findings for all‐cause mortality and myocardial infarction show a lack of statistical significance, and are based on very little data. Equivalence between RIs and ACE inhibitors cannot therefore be established based on the results of this review. </p> <p>Our review indicates that RIs show a similar incidence of adverse events, serious adverse events and WDAEs as ACE inhibitors. Reviews of short‐term placebo‐controlled trials have shown that aliskiren does not increase withdrawals due to adverse effects, compared to placebo (<a href="./references#CD012569-bbs2-0045" title="MusiniVM , LawrenceKA , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007066. [DOI: 10.1002/14651858.CD007066.pub3]">Musini 2017</a>). These findings suggest that aliskiren could be used for the treatment of hypertension. It is important to remember that regulatory agencies have warned that combined use of angiotensin‐converting enzyme inhibitors, angiotensin II receptor antagonists or aliskiren is not recommended, particularly in people with diabetes or renal impairment (<a href="./references#CD012569-bbs2-0030" title="European Medicines Agency. Combined use of medicines affecting the renin angiotensin system (RAS) to be restricted – CHMP endorses PRAC recommendation. www.ema.europa.eu/en/documents/press-release/combined-use-medicines-affecting-renin-angiotensin-system-ras-be-restricted-chmp-endorses-prac_en.pdf2014.">EMA 2014</a>; <a href="./references#CD012569-bbs2-0034" title="US Drugs and Food Administration. FDA Drug Safety Communication: New warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warning-and-contraindication-blood-pressure-medicines-containing#professionals2012.">FDA 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012569-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012569-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012569-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.6 SBP." data-id="CD012569-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.6 SBP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.7 DBP." data-id="CD012569-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Renin inhibitors vs. ACE inhibitors, outcome: 1.7 DBP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 1: All‐cause mortality" data-id="CD012569-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 2: Fatal or non‐fatal myocardial infarction" data-id="CD012569-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 2: Fatal or non‐fatal myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 3: Adverse events" data-id="CD012569-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 3: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 4: Fatal or non‐fatal serious adverse events" data-id="CD012569-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 4: Fatal or non‐fatal serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 5: Withdrawal due to adverse effects (WDAE)" data-id="CD012569-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 5: Withdrawal due to adverse effects (WDAE) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 6: SBP" data-id="CD012569-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 6: SBP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012569-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/urn:x-wiley:14651858:media:CD012569:CD012569-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 7: DBP" data-id="CD012569-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_t/tCD012569-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Renin inhibitors vs. ACE inhibitors, Outcome 7: DBP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/media/CDSR/CD012569/image_n/nCD012569-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012569-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Renin inhibitors compared to ACE inhibitors for primary hypertension</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Renin inhibitors compared to ACE inhibitors for primary hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with primary hypertension<br/><b>Setting:</b> ambulatory clinics<br/><b>Intervention:</b> Renin inhibitors<br/><b>Comparison:</b> ACE inhibitors </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ACE inhibitors</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with Renin inhibitors</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow‐up: range 4 weeks to 36.6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5962<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.93 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1,000<br/>(9 fewer to 24 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal or non‐fatal myocardial infarction<br/>follow‐up: range 8 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>957<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.22 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/>(5 fewer to 16 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6007<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.93 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 fewer per 1000<br/>(34 fewer to 15 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal or non‐fatal serious adverse events<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6007<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/>(0.89 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 more per 1000<br/>(3 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse effects (WDAE)<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6008<br/>(10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.68 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 fewer per 1000<br/>(19 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SBP<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5001<br/>(9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.72 mm Hg lower<br/>(2.47 lower to 0.97 lower) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DBP<br/>follow‐up: range 4 weeks to 54 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5001<br/>(9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.18 lower<br/>(1.65 lower to 0.72 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% </p> <p>CI).<br/><br/><b>CI:</b> Confidence interval; <b>DBP:</b> diastolic blood pressure; <b>RR:</b> Risk ratio; <b>SBP:</b> systolic blood pressure </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to high risk of source of funding bias.<br/><sup>b</sup>Results almost entirely from <a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. ">ATMOSPHERE 2016</a>, 60% hypertensive heart‐failure participants at baseline.<br/><sup>c</sup>Downgraded due to wide confidence interval.<br/><sup>d</sup>Downgraded due to risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Renin inhibitors compared to ACE inhibitors for primary hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012569-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean Age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Co‐morbidity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Add‐on drugs</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline SBP/DBP (mm Hg)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0001" title="DuprezDA , MungerMA , BothaJ , KeefeDL , CharneyAN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension2010;24(9):606-8. "><b>AGELESS 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 72.0</p> <p>C: 72.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 21.7%; ramipril 19.6%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150‐300 mg/day</p> <p>C: Ramipril 5‐10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 12.5 ‐ 25 mg/day or</p> <p>HCTZ 12.5 ‐ 25 mg/day +amlodipine 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 156.5/85.5</p> <p>C: 156.6/86.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0002" title="Efficacy of aliskiren compared to ramipril in the treatment of moderate systolic hypertensive patients – ALIAS study. https://clinicaltrials.gov/ct2/show/NCT01042392. "><b>ALIAS 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 60.1</p> <p>C: 59.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150‐300 mg/day</p> <p>C: Ramipril 5‐10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 166.4/89.9</p> <p>C: 166.3/90.9</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0003" title="AndersenK , WeinbergerMH , ConstanceCM , AliMA , JinJ , PrescottMF , et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of Renin-Angiotensin-Aldosterone System2009;10(3):157-67. AndersenK , WeinbergerMH , EganB , ConstanceCM , AliMA , JinJ , et al. Comparative efficacy and safety of aliskiren, an oral directrenin inhibitor, and ramipril in hypertension: a 6-month,randomized, double-blind trial. Journal of Hypertension2008;26(3):589-99. AndersenK , WeinbergerMH , EganB , ConstanceCM , WrightM , LukashevichV , et al. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovascular Therapeutics2010;28(6):344-9. "><b>Andersen 2008</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 53.4</p> <p>C: 53.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 10%; ramipril 11.6%.</p> <p>Baseline metabolic syndrome: aliskiren 40.7%; ramipril 43.3%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C: Ramipril 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 12.5 ‐ 25 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 151.3/98.8</p> <p>C: 151.4/98.9</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0004" title="McMurrayJJ , KrumH , AbrahamWT , DicksteinK , KøberLV , DesaiAS , et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine2016;374(16):1521-32. "><b>ATMOSPHERE 2016</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 63.3</p> <p>C1: 63.3</p> <p>C2: 63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heart failure as inclusion criterion;</p> <p>Baseline diabetes: aliskiren 26.8%;</p> <p>enalapril 27.9%; enalapril + aliskiren 28.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C1: Enalapril 5 ‐ 10 mg/day</p> <p>C2: Enalapril 5 ‐ 10 mg/day + Aliskiren 150 ‐ 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Optimal heart failure therapy, including beta blockers, but with the exception of ACE inhibitors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> <p>Note: Numbers of</p> <p>hypertensive</p> <p>participants at baseline, n(%):</p> <p>T: 1460 (62.4%)</p> <p>C1: 1425 (61.0%)</p> <p>C2: 1447 (61.8%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0005" title="Jones-BurtonC , RubinoJ , RoyS , MaiY , MeehanA , BelletM , et al. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. Journal of the American Society of Hypertension2010;4(5):219-26. [DOI: 10.1016/j.jash.2010.06.006] [PMID: 20705534]"><b>Jones‐Burton 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 52.8</p> <p>T2: 52.8</p> <p>C1: 51.5</p> <p>C2: 53.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1:MK‐8141 250 mg/day</p> <p>T2:MK‐8141 500 mg/day</p> <p>C1: Enalapril 20 mg/day</p> <p>C2: Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 150.2/93.8</p> <p>T2: 149.7/94.2</p> <p>C1: 150.6/95.1</p> <p>C2: 151.9/93.6</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0006" title="NCT00631917. A study evaluating the gastrointestinal (GI) safety and tolerability of aliskiren compared to ramipril in essential hypertension. clinicaltrials.gov/ct2/show/NCT00631917 (first received 10 March 2008). "><b>NCT00631917 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 59.3</p> <p>C: 59.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 22.1%; ramipril 25.1%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C: Ramipril 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 12.5 ‐ 25 mg/day or HCTZ 12.5 ‐ 25 mg/ay + amlodipine 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0007" title="PalatiniP , JungW , ShlyakhtoE , BothaJ , BushC , KeefeDL . Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. Journal of Human Hypertension2010;24(2):93-103. "><b>Palatini 2010</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 53.5</p> <p>C1: 53.9</p> <p>C2: 53.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C1: Ramipril 5 ‐ 10 mg/day</p> <p>C2: Irbesartan 150 ‐ 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 145.5/93</p> <p>C1:145.8/92.4</p> <p>C2:145.4/93.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0008" title="StrasserRH , PuigJG , FarsangC , CroketM , LiJ , Van IngenH . A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension2007;21(10):780-7. "><b>Strasser 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 55.3</p> <p>C: 55.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 12.0%; lisinopril 13.8%.</p> <p>Baseline metabolic syndrome: aliskiren 52.8%; lisinopril 58.6%</p> <p>Baseline hypercholesterolemia: aliskiren 16.8%; lisinopril 15.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C: Lisinopril 20 ‐ 40 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCTZ 25 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 163.4/108.4</p> <p>C: 161.7/108.0</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0009" title="UresinY , TaylorAA , KiloC , TschöpeD , SantonastasoM , IbramG , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin-Angiotensin-Aldosterone System2007;8(4):190-200. "><b>Uresin 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 60.0</p> <p>C1: 59.9</p> <p>C2: 59.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type 1 or 2 diabetes mellitus as inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: Aliskiren 150 ‐ 300 mg/day</p> <p>C1: Ramipril 5 ‐ 10 mg/day</p> <p>C2: Aliskiren 150 ‐ 300 mg/day+ Ramipril 5 ‐ 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T: 157.4/98.4</p> <p>C1: 155.9/98.2</p> <p>C2: 156.5/98.4</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0010" title="VerdecchiaP , CalvoC , MöckelV , KeelingL , SatlinA . Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure2007;16(6):381-91. "><b>Verdecchia 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 73.6</p> <p>T2: 73.2</p> <p>T3: 73.0</p> <p>C: 74.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 75 mg 13.2%; aliskiren 150 mg 11.9%; aliskiren 300 mg 11.7%; lisinopril 7.0% </p> <p>Baseline metabolic syndrome: aliskiren 75 mg 27.5%; aliskiren 150 mg 22.6%; aliskiren 300 mg 24.5%; lisinopril 23.3% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: Aliskiren 75 mg/day</p> <p>T2: Aliskiren 150 mg/day</p> <p>T3: Aliskiren 300 mg/day</p> <p>C: Lisinopril 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 160.4/88.0</p> <p>T2: 160.2/89.3</p> <p>T3: 160.7/90.1</p> <p>C: 161.4/88.1</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD012569-bbs2-0011" title="GuoJQ , WangHY , SunNL . Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Chinese Medical Journal (Engl)2013;126(7):1242-6. NCT00529451. Safety and efficacy of aliskiren 300 mg, 150 mg and 75 mg in patients with essential hypertension compared to ramipril 5 mg. clinicaltrials.gov/ct2/show/NCT00529451 (first received 14 September 2007). ZhuJR , SunNL , YangK , HuJ , XuG , HongHS , et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertension Research2012;35(1):28-33. "><b>Zhu 2012</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 52.7</p> <p>T2: 53.3</p> <p>T3: 53.8</p> <p>C: 52.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline diabetes: aliskiren 75 mg 10.5%;</p> <p>aliskiren 150 mg 9.6%;</p> <p>aliskiren 300 mg 10.9%;</p> <p>ramipril 5 mg 15.2%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: Aliskiren 75 mg/day</p> <p>T2: Aliskiren 150 mg/day</p> <p>T3: Aliskiren 300 mg/day</p> <p>C: Ramipril 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T1: 147.3/98.9</p> <p>T2: 146.8/98.5</p> <p>T3: 148.9/98.9</p> <p>C1: 148.5/98.8</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>C: control group; DBP: diastolic blood pressure; HCTZ: hydrochlorothiazide; N: total number of participants randomized in each trial; T: test group; NA: not available; SBP: systolic blood pressure </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/full#CD012569-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012569-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Renin inhibitors vs. ACE inhibitors</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Fatal or non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.22, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Fatal or non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.89, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Withdrawal due to adverse effects (WDAE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 SBP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.72 [‐2.47, ‐0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 DBP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐1.65, ‐0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Renin inhibitors vs. ACE inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012569.pub2/references#CD012569-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012569.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012569-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012569-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012569-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012569-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012569-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012569-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012569-note-0009">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD012569-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012569-note-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012569-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012569-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012569\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012569\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012569\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012569\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012569\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012569.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012569.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012569.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012569.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012569.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718003141"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012569.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718003145"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012569.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc5b94e2cf49c',t:'MTc0MDcxODAwMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 